rna estimation Search Results


rna hs assay kit  (Vazyme Biotech Co)
95
Vazyme Biotech Co rna hs assay kit
Rna Hs Assay Kit, supplied by Vazyme Biotech Co, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rna hs assay kit/product/Vazyme Biotech Co
Average 95 stars, based on 1 article reviews
rna hs assay kit - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
cdna  (Bio-Rad)
99
Bio-Rad cdna
Cdna, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdna/product/Bio-Rad
Average 99 stars, based on 1 article reviews
cdna - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
graphpad prism software  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism software
Graphpad Prism Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism software - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
bnt162b2 mrna vaccine  (BioNTech)
90
BioNTech bnt162b2 mrna vaccine
Characteristics of the study population by vaccination status.
Bnt162b2 Mrna Vaccine, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bnt162b2 mrna vaccine/product/BioNTech
Average 90 stars, based on 1 article reviews
bnt162b2 mrna vaccine - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
easypure viral dna rna extraction kit  (Thermo Fisher)
99
Thermo Fisher easypure viral dna rna extraction kit
Characteristics of the study population by vaccination status.
Easypure Viral Dna Rna Extraction Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/easypure viral dna rna extraction kit/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
easypure viral dna rna extraction kit - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
ribotm mrna/lncrna qrt-pcr starter kit  (Ribobio co)
90
Ribobio co ribotm mrna/lncrna qrt-pcr starter kit
Characteristics of the study population by vaccination status.
Ribotm Mrna/Lncrna Qrt Pcr Starter Kit, supplied by Ribobio co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ribotm mrna/lncrna qrt-pcr starter kit/product/Ribobio co
Average 90 stars, based on 1 article reviews
ribotm mrna/lncrna qrt-pcr starter kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
glyceraldehyde 3 phosphate dehydrogenase  (Thermo Fisher)
99
Thermo Fisher glyceraldehyde 3 phosphate dehydrogenase
Characteristics of the study population by vaccination status.
Glyceraldehyde 3 Phosphate Dehydrogenase, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/glyceraldehyde 3 phosphate dehydrogenase/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
glyceraldehyde 3 phosphate dehydrogenase - by Bioz Stars, 2026-05
99/100 stars
  Buy from Supplier
mrna copy number  (PrimerDesign Inc)
90
PrimerDesign Inc mrna copy number
Characteristics of the study population by vaccination status.
Mrna Copy Number, supplied by PrimerDesign Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mrna copy number/product/PrimerDesign Inc
Average 90 stars, based on 1 article reviews
mrna copy number - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
biophotometer d30  (Eppendorf AG)
95
Eppendorf AG biophotometer d30
Characteristics of the study population by vaccination status.
Biophotometer D30, supplied by Eppendorf AG, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biophotometer d30/product/Eppendorf AG
Average 95 stars, based on 1 article reviews
biophotometer d30 - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
plasma cell free dna cfdna levels dna extraction method dna  (MACHEREY NAGEL)
93
MACHEREY NAGEL plasma cell free dna cfdna levels dna extraction method dna
Characteristics of the study population by vaccination status.
Plasma Cell Free Dna Cfdna Levels Dna Extraction Method Dna, supplied by MACHEREY NAGEL, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/plasma cell free dna cfdna levels dna extraction method dna/product/MACHEREY NAGEL
Average 93 stars, based on 1 article reviews
plasma cell free dna cfdna levels dna extraction method dna - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
versant hiv-1 rna  (Siemens AG)
90
Siemens AG versant hiv-1 rna
Study characteristics and dried blood spot specimen preparation process.
Versant Hiv 1 Rna, supplied by Siemens AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/versant hiv-1 rna/product/Siemens AG
Average 90 stars, based on 1 article reviews
versant hiv-1 rna - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
qsep 100 dna/rna analyzer  (BiOptic Inc)
90
BiOptic Inc qsep 100 dna/rna analyzer
Study characteristics and dried blood spot specimen preparation process.
Qsep 100 Dna/Rna Analyzer, supplied by BiOptic Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/qsep 100 dna/rna analyzer/product/BiOptic Inc
Average 90 stars, based on 1 article reviews
qsep 100 dna/rna analyzer - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

Image Search Results


Characteristics of the study population by vaccination status.

Journal: PLoS Medicine

Article Title: Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

doi: 10.1371/journal.pmed.1003992

Figure Lengend Snippet: Characteristics of the study population by vaccination status.

Article Snippet: The aim of this study was to estimate the effectiveness of 2 or 3 doses of the BNT162b2 mRNA (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccines against SARS-CoV-2 infection and COVID-19 hospitalization in an Alpha-, Delta-, or Omicron-dominant period by time since vaccination, and by 2 age groups, those aged 12 to 59 years and those 60 years and above.

Techniques: Northern Blot

Adjusted VE of 2 doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Alpha, Delta, or Omicron variant by age groups (12–59 years and 60 years or above).

Journal: PLoS Medicine

Article Title: Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

doi: 10.1371/journal.pmed.1003992

Figure Lengend Snippet: Adjusted VE of 2 doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Alpha, Delta, or Omicron variant by age groups (12–59 years and 60 years or above).

Article Snippet: The aim of this study was to estimate the effectiveness of 2 or 3 doses of the BNT162b2 mRNA (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccines against SARS-CoV-2 infection and COVID-19 hospitalization in an Alpha-, Delta-, or Omicron-dominant period by time since vaccination, and by 2 age groups, those aged 12 to 59 years and those 60 years and above.

Techniques: Infection, Variant Assay

Adjusted VE of 3 doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Delta or Omicron variant by age groups (18–59 years and 60 years or above).

Journal: PLoS Medicine

Article Title: Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

doi: 10.1371/journal.pmed.1003992

Figure Lengend Snippet: Adjusted VE of 3 doses BNT162b2 mRNA or mRNA-1273 against SARS-CoV-2 infection with the Delta or Omicron variant by age groups (18–59 years and 60 years or above).

Article Snippet: The aim of this study was to estimate the effectiveness of 2 or 3 doses of the BNT162b2 mRNA (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccines against SARS-CoV-2 infection and COVID-19 hospitalization in an Alpha-, Delta-, or Omicron-dominant period by time since vaccination, and by 2 age groups, those aged 12 to 59 years and those 60 years and above.

Techniques: Infection, Variant Assay

Adjusted VE of 2 doses BNT162b2 mRNA or mRNA-1273 against COVID-19 hospitalization following infection with the Alpha, Delta, or Omicron variant by age groups (12–59 years and 60 years or above).

Journal: PLoS Medicine

Article Title: Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

doi: 10.1371/journal.pmed.1003992

Figure Lengend Snippet: Adjusted VE of 2 doses BNT162b2 mRNA or mRNA-1273 against COVID-19 hospitalization following infection with the Alpha, Delta, or Omicron variant by age groups (12–59 years and 60 years or above).

Article Snippet: The aim of this study was to estimate the effectiveness of 2 or 3 doses of the BNT162b2 mRNA (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccines against SARS-CoV-2 infection and COVID-19 hospitalization in an Alpha-, Delta-, or Omicron-dominant period by time since vaccination, and by 2 age groups, those aged 12 to 59 years and those 60 years and above.

Techniques: Infection, Variant Assay

Adjusted VE of 3 doses BNT162b2 mRNA or mRNA-1273 against COVID-19 hospitalization following infection with the Delta or Omicron variant by age groups (18–59 years and ≥60 years).

Journal: PLoS Medicine

Article Title: Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study

doi: 10.1371/journal.pmed.1003992

Figure Lengend Snippet: Adjusted VE of 3 doses BNT162b2 mRNA or mRNA-1273 against COVID-19 hospitalization following infection with the Delta or Omicron variant by age groups (18–59 years and ≥60 years).

Article Snippet: The aim of this study was to estimate the effectiveness of 2 or 3 doses of the BNT162b2 mRNA (Pfizer/BioNTech) or mRNA-1273 (Moderna) vaccines against SARS-CoV-2 infection and COVID-19 hospitalization in an Alpha-, Delta-, or Omicron-dominant period by time since vaccination, and by 2 age groups, those aged 12 to 59 years and those 60 years and above.

Techniques: Infection, Variant Assay

Study characteristics and dried blood spot specimen preparation process.

Journal: PLoS Medicine

Article Title: The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis

doi: 10.1371/journal.pmed.1004076

Figure Lengend Snippet: Study characteristics and dried blood spot specimen preparation process.

Article Snippet: For the Abbott RealTi m e HIV-1 two-spot, Abbott RealTi m e HIV-1 one-spot, Biocentric Generic HIV Charge Virale, bioMérieux NucliSENS EasyQ HIV-1, Hologic Aptima, Roche COBAS TaqMan FVE, Roche COBAS TaqMan SPEX, and Siemens VERSANT HIV-1 RNA technologies, 59.28%, 68.71%, 38.04%, 52.54%, 50.40%, 62.03%, 33.45%, 47.22% of dried blood spot specimen test results were within the standard deviation of +/−0.3 log copies/ml of the paired plasma test result, respectively ( ).

Techniques: Clinical Proteomics, Isolation, Lysis, Extraction, Sample Prep

Analytical and clinical metrics for each study.

Journal: PLoS Medicine

Article Title: The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis

doi: 10.1371/journal.pmed.1004076

Figure Lengend Snippet: Analytical and clinical metrics for each study.

Article Snippet: For the Abbott RealTi m e HIV-1 two-spot, Abbott RealTi m e HIV-1 one-spot, Biocentric Generic HIV Charge Virale, bioMérieux NucliSENS EasyQ HIV-1, Hologic Aptima, Roche COBAS TaqMan FVE, Roche COBAS TaqMan SPEX, and Siemens VERSANT HIV-1 RNA technologies, 59.28%, 68.71%, 38.04%, 52.54%, 50.40%, 62.03%, 33.45%, 47.22% of dried blood spot specimen test results were within the standard deviation of +/−0.3 log copies/ml of the paired plasma test result, respectively ( ).

Techniques: Clinical Proteomics, Reverse Transcription Polymerase Chain Reaction

Meta-analysis of clinical metrics overall and for each viral load technology.

Journal: PLoS Medicine

Article Title: The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis

doi: 10.1371/journal.pmed.1004076

Figure Lengend Snippet: Meta-analysis of clinical metrics overall and for each viral load technology.

Article Snippet: For the Abbott RealTi m e HIV-1 two-spot, Abbott RealTi m e HIV-1 one-spot, Biocentric Generic HIV Charge Virale, bioMérieux NucliSENS EasyQ HIV-1, Hologic Aptima, Roche COBAS TaqMan FVE, Roche COBAS TaqMan SPEX, and Siemens VERSANT HIV-1 RNA technologies, 59.28%, 68.71%, 38.04%, 52.54%, 50.40%, 62.03%, 33.45%, 47.22% of dried blood spot specimen test results were within the standard deviation of +/−0.3 log copies/ml of the paired plasma test result, respectively ( ).

Techniques: Clinical Proteomics

Meta-analysis of clinical metrics overall and for each viral load technology and protocol for treatment failure thresholds below 1,000 copies/ml.

Journal: PLoS Medicine

Article Title: The performance of using dried blood spot specimens for HIV-1 viral load testing: A systematic review and meta-analysis

doi: 10.1371/journal.pmed.1004076

Figure Lengend Snippet: Meta-analysis of clinical metrics overall and for each viral load technology and protocol for treatment failure thresholds below 1,000 copies/ml.

Article Snippet: For the Abbott RealTi m e HIV-1 two-spot, Abbott RealTi m e HIV-1 one-spot, Biocentric Generic HIV Charge Virale, bioMérieux NucliSENS EasyQ HIV-1, Hologic Aptima, Roche COBAS TaqMan FVE, Roche COBAS TaqMan SPEX, and Siemens VERSANT HIV-1 RNA technologies, 59.28%, 68.71%, 38.04%, 52.54%, 50.40%, 62.03%, 33.45%, 47.22% of dried blood spot specimen test results were within the standard deviation of +/−0.3 log copies/ml of the paired plasma test result, respectively ( ).

Techniques: